Summit Therapeutics (SMMT) Retained Earnings: 2016-2025
Historic Retained Earnings for Summit Therapeutics (SMMT) over the last 10 years, with Sep 2025 value amounting to -$2.1 billion.
- Summit Therapeutics' Retained Earnings fell 79.91% to -$2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 billion, marking a year-over-year decrease of 79.91%. This contributed to the annual value of -$1.2 billion for FY2024, which is 22.28% down from last year.
- Per Summit Therapeutics' latest filing, its Retained Earnings stood at -$2.1 billion for Q3 2025, which was down 12.58% from -$1.8 billion recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Retained Earnings ranged from a high of -$228.4 million in Q1 2021 and a low of -$2.1 billion during Q3 2025.
- Its 3-year average for Retained Earnings is -$1.2 billion, with a median of -$1.1 billion in 2024.
- Data for Summit Therapeutics' Retained Earnings shows a maximum YoY tumbled of 991.33% (in 2021) over the last 5 years.
- Summit Therapeutics' Retained Earnings (Quarterly) stood at -$299.5 million in 2021, then fell by 26.30% to -$378.3 million in 2022, then crashed by 162.54% to -$993.3 million in 2023, then dropped by 22.28% to -$1.2 billion in 2024, then tumbled by 79.91% to -$2.1 billion in 2025.
- Its last three reported values are -$2.1 billion in Q3 2025, -$1.8 billion for Q2 2025, and -$1.3 billion during Q1 2025.